PMID- 30417023
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 2329-0501 (Print)
IS  - 2329-0501 (Electronic)
IS  - 2329-0501 (Linking)
VI  - 11
DP  - 2018 Dec 14
TI  - P-FN12, an H4R-Based Epitope Vaccine Screened by Phage Display, Regulates the 
      Th1/Th2 Balance in Rat Allergic Rhinitis.
PG  - 83-91
LID - 10.1016/j.omtm.2018.09.004 [doi]
AB  - Allergic rhinitis (AR) involves antigen-specific immune-inflammation of the nasal 
      mucosa. Classical therapy for AR targets the histamine pathway, e.g., histamine 
      receptor blockers. Histamine H4 receptor (H4R) was suggested as a novel 
      therapeutic target due to its wide expression on almost all immune-related cells. 
      A 12-mer random peptide library was used to select the specific epitope of the 
      H4R. The phage clone showing the highest degree of activation was verified and 
      translated to the corresponding peptide. The peptide FNKWMDCLSVTH, designated as 
      P-FN12, was bound by H4R monoclonal antibody (mcAb) with high affinity. Moreover, 
      the P-FN12 + CTB@Lipo-formulated vaccine, used as nasal drops, decreased allergic 
      symptoms such as sneezing and nasal rubbing in a rat model. The level of 
      ovalbumin (OVA)-specific immunoglobulin E (IgE) decreased significantly after 
      vaccine administration. It also elicited increased levels of interferon (IFN)-gamma 
      and interleukin-2 (IL-2) but a decreased level of IL-4, and it elevated the T 
      helper type 1 (Th1):T helper type 2 (Th2) cell ratio in peripheral blood 
      mononuclear cell cultures. Our results indicated that the reduction of allergic 
      inflammation by P-FN12-based vaccine was related to a decrease in production of 
      OVA-specific IgE, Th2 immunity, and tissue eosinophilia. P-FN12 + CTB@Lipo is a 
      promising vaccine that could suppress Th2 response and enhance the induction of 
      Th1 cells in an AR model.
FAU - Wang, Yuqian
AU  - Wang Y
AD  - Scientific Research Center, China-Japan Union Hospital of Jilin University, 
      Changchun, Jilin 130033, China.
FAU - Sha, Jichao
AU  - Sha J
AD  - Department of Otorhinolaryngology Head and Neck Surgery, China-Japan Union 
      Hospital of Jilin University, Changchun, Jilin 130033, China.
FAU - Wang, Heng
AU  - Wang H
AD  - Environmental Protection Research Institute of Changchun, 7930 Weixing Road, 
      Changchun 130022, China.
FAU - An, Lifeng
AU  - An L
AD  - Department of Otorhinolaryngology Head and Neck Surgery, China-Japan Union 
      Hospital of Jilin University, Changchun, Jilin 130033, China.
FAU - Liu, Tie
AU  - Liu T
AD  - Biobank, China-Japan Union Hospital of Jilin University, 126 Xiantai Street, 
      Changchun 130031, China.
FAU - Li, Lin
AU  - Li L
AD  - Department of Otorhinolaryngology Head and Neck Surgery, China-Japan Union 
      Hospital of Jilin University, Changchun, Jilin 130033, China.
LA  - eng
PT  - Journal Article
DEP - 20181004
PL  - United States
TA  - Mol Ther Methods Clin Dev
JT  - Molecular therapy. Methods & clinical development
JID - 101624857
PMC - PMC6216098
OTO - NOTNLM
OT  - Th1/Th2 responses
OT  - allergic rhinitis
OT  - epitope
OT  - histamine receptor 4
OT  - phage display peptide library
EDAT- 2018/11/13 06:00
MHDA- 2018/11/13 06:01
PMCR- 2018/10/04
CRDT- 2018/11/13 06:00
PHST- 2018/05/01 00:00 [received]
PHST- 2018/09/25 00:00 [accepted]
PHST- 2018/11/13 06:00 [entrez]
PHST- 2018/11/13 06:00 [pubmed]
PHST- 2018/11/13 06:01 [medline]
PHST- 2018/10/04 00:00 [pmc-release]
AID - S2329-0501(18)30095-0 [pii]
AID - 10.1016/j.omtm.2018.09.004 [doi]
PST - epublish
SO  - Mol Ther Methods Clin Dev. 2018 Oct 4;11:83-91. doi: 10.1016/j.omtm.2018.09.004. 
      eCollection 2018 Dec 14.